kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ZM 336372, 10 mg  

ZM 336372, 10 mg


Synonyms: ZM447439, ZM-447439
selective ATP-competitive inhibitor of Aurora B kinase

More details


Availability: within 3 days

300,00 €

Background: ZM 336372 was first described as a potent and selective inhibitor of C-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf) which shows a 10-fold selectivity over B-Raf. The drug showed a paradoxical response when used in cell culture assays. So treatment with ZM 336372 results in a strong activation of Raf/MEK/ERK pathway evidenced by phosphorylation of C-Raf and ist downstream pathway mediators. In tumor cells the drug inhibits cellular proliferaton by inducing cell cycle inhibitors such as p21 and p18 and reducing levels of bioactive hormones.  

Chemical formula: C23H23N3O3
Molecular Weight:  398,45 g/mol
Purity:  > 99,5%
Appearance:  white solid
Solubility:  DMSO to 100 mM
CAS Nr. 208260-29-1  

Product specific literature references:

Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. (1999) " Paradoxical activation of Raf by a novel Raf inhibitor." Chem. Biol.6(8):559-68

Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. (2005) " ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells." Mol Cancer Ther. 4(6):910-7.

Kunnimalaiyaan M, Chen H. (2006) " The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?" Anticancer Drugs. 17(2):139-42.

Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H. (2006) "ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells." J Surg Res.133(1):42-5.

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.